We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.

Pharmidex is pleased to announce that Janette Dalay Robertson , Business Development Manager, will be attending the Milner Seminar May 2026 hosted by the Milner Therapeutics Institute at the Jeffrey Cheah Biomedical Centre , Cambridge, on 19 May 2026 from 4:00–5:00pm. The seminar will bring together experts from academia and industry to discuss innovation and collaboration in drug discovery and translational science. Pharmidex will also be exhibiting at the event. Janette will be near the café in the Jeffrey Cheah Biomedical Centre from 11am tomorrow, so if you would like to discuss drug discovery, preclinical development, bioanalysis, or potential collaborations, please feel free to stop by for a chat before the seminar begins. Looking forward to connecting with researchers, biotech innovators, and industry partners throughout the day!